Recordati SpA (RICFY)
13.34
-0.04
(-0.34%)
USD |
OTCM |
Dec 16, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.01B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 15.67% |
| Valuation | |
| PE Ratio | 24.29 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.533 |
| Price to Book Value | 5.257 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1577 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8303 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients. |
| URL | https://www.recordati.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 21, 2025 (est.) |
| Last Earnings Release | Nov. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 22, 2024 |
Ratings
Profile
| Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients. |
| URL | https://www.recordati.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 21, 2025 (est.) |
| Last Earnings Release | Nov. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 22, 2024 |